Long COVID patients show distinct immune, hormone responses to virus
Yale School of Medicine
New Cleveland Clinic-led research shows commonly used COVID-19 anti-viral drugs Paxlovid (nirmatrelvir) and Lagevrio (molnupiravir) reduce risk of hospitalization and death in high-risk patients with mild disease, even with Omicron subvariants.
Tuberculosis is old—ancient even. The infectious bacterial disease that plagued Old Testament Israelites and took down pharaohs was eventually stunted by vaccinations, antibiotics, and public health measures like isolation, but it hasn’t been cured yet. More than a million people around the world still die from TB every year.
A three-year, $2.3 million grant to study post-pandemic eviction stress and mental health has been awarded to researchers from UTHealth Houston by the National Institute of Nursing Research, part of the National Institutes of Health.
During the COVID pandemic, U.S. states and territories created websites to share relevant public health information. But a new study finds the sites don’t meet accessibility standards.
People who have experienced brain fog, confusion, pain, and extreme fatigue for months or longer after being infected with the COVID-19 virus exhibit different immune and hormonal responses to the virus than those not diagnosed with long COVID.
Researchers at the Francis Crick Institute, the University of Cambridge, Imperial College London, the University of Liverpool, the University of Cape Town and UKHSA have uncovered a link between an antiviral drug for COVID-19 infections called molnupiravir and a pattern of mutations in the SARS-CoV-2 virus.
New research used engineered mice to compare SARS-COV-2 omicron subvariants and found one of them – BA.5 – was more virulent likely due to its ability to rapidly replicate early during infection.
Research conducted at Mount Sinai and Yale confirms long COVID is a biological disease by showing blood biomarkers that can predict who has it
Rutgers develops a prognosis tool to help hospitals improve care.
A Rutgers infectious disease expert explains what you need to know about this year’s flu, COVID and new RSV shots
A study has revealed new details about a key population of immune system cells critical to successful vaccination against the pandemic virus, SARS-CoV-2.
In a study published online in CELL today, scientists at UCSF QBI, University College London and the Icahn School of Medicine at Mount Sinai reported breakthrough findings on convergent evolutionary mechanisms shared by COVID-19 variants, allowing them to overcome both adaptive and innate immune system barriers.
Members of the Intergovernmental Negotiating Body Bureau continue the discussion on infodemic management in light of circulation of misinformation through social media during public health emergencies.
In August 2023, Americans made nearly a million calls for help to the 211 emergency resources helpline, according to 211 Counts, a national tracking system in 36 states developed by the Brown School’s Health Communication Research Laboratory at Washington University in St. Louis.
As cities brace for a confluence of flu, COVID-19, pneumonia, and RSV infections this fall, the American Thoracic Society announced that five new health systems have partnered with the Society to improve vaccination rates.
Findings from a nationwide, multicenter study led by Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health suggest that patients with COVID-19 have less chance of developing post-COVID conditions — commonly known as long COVID — if they receive early treatment with plasma from convalescent (recovered) COVID patients that contain antibodies against SARS-CoV-2, the virus that causes COVID-19.
Rutgers researchers have developed a way of detecting the early onset of deadly infectious diseases using a test so ultrasensitive that it could someday revolutionize medical approaches to epidemics.
The US CDC (Centers for Disease Control and Prevention) funded Global COVID Vaccine Safety Project has generated background incidence rates on a range of conditions designated as AESI (Adverse Events of Special Interest) for COVID-19 vaccine safety monitoring. Conditions studied included myocarditis, pulmonary embolism, and Guillain-Barré syndrome.
Cases of Prolonged Grief Disorder among people bereaved during the COVID-19 pandemic are likely to be significantly higher than pre-pandemic, indicates new research from Cardiff University and the University of Bristol.
The use of cell therapy to treat COVID-19 patients can reduce the risk of death from the disease by 60%, according to a systematic review and meta-analysis conducted by researchers at the University of São Paulo (USP) in Brazil, in partnership with colleagues in Germany and the United States.
Discovery from the lab of Youyang Zhao, PhD, from Stanley Manne Children’s Research Institute at Ann & Robert H. Lurie Children’s Hospital of Chicago offers promising treatment approaches for acute respiratory distress syndrome (ARDS) in the elderly that can be caused by severe COVID-19, pneumonia, flu or sepsis.
One in three people exposed to SARS-CoV2 is infected, and as many as two in five with the Omicron variant. In the case of immunity — conferred by vaccination, infection or a combination of the two — this rate drops to one in ten.
Customers showing up even when they were sick, not agreeing with the restrictions, and many new tasks for staff. These are factors that contributed to heavier workloads and tougher work environments in pharmacies during the pandemic, a study reveals.
In a new study, researchers analyze the world’s largest social media platform and its efforts to remove Covid-19 vaccine misinformation during the pandemic.
A social media campaign launched in 2022 helped encourage some Nigerians to roll up their sleeves for a COVID vaccine, according to a study published today in PLOS ONE.
The outbreak of the COVID pandemic in 2020 has once again shown how important reliable and rapid detection methods are to initiate effective measures to combat a pandemic.
As a result of vaccination or infection, our immune system produces antibodies that attach to the spike protein of SARS-CoV-2, preventing the virus from entering and replicating within cells.
People who bought firearms during the height of the COVID-19 pandemic have much higher rates of recent suicidal thoughts, self-harm behaviors, and intimate partner violence, a new study suggests, compared with other firearm owners and people who do not own firearms.
A late summer increase in COVID-19-related hospitalizations and the emergence of new coronavirus variants raises concerns about how best to counter infection and who should receive the newly-approved vaccines.
A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University found no symptomatic or clinical benefit to taking the antidepressant fluvoxamine at a dosage of 100 mg twice daily for 13 days for the treatment of mild-to-moderate COVID-19 symptoms.
Ahead of discussions at the United Nations General Assembly (UNGA78), the trade association representing the innovative pharmaceutical industry, the IFPMA, has warned that current pandemic preparedness plans should not undermine what worked well in response to COVID-19 and must support both “innovation and equity.”
The risk of developing long COVID is significantly lower following an infection with the Omicron variant than after an infection with earlier coronavirus variants. This was the finding of a study by University Medicine Halle, which was published in the “International Journal of Infectious Diseases”.
New UC Riverside research has revealed COVID’s Achilles heel — its dependence on key human proteins for its replication — which can be used to prevent the virus from making people sick.
High performance computing resources, advanced epidemiological models, and powerful algorithms will make dealing with future crises much easier, thanks to research led by Argonne National Laboratory.
It still feels like summer outside, but it’s time to prepare for the 2023-24 flu season.
$13 million will fund a multidisciplinary, multi-institution team effort to develop stronger and more versatile vaccines
The Department of Energy’s Office of Science has selected three Oak Ridge National Laboratory research teams to receive funding through DOE’s new Biopreparedness Research Virtual Environment, or BRaVE, initiative. BRaVE, announced earlier this year, aims to build on biopreparedness research that delivered high-impact results in the fight against COVID-19.
Type 1 diabetes is an autoimmune disease leading to an impaired glucose metabolism and requires life-long administration of insulin. While the cause of the autoimmunity reaction is still unclear, viral infections in young children are proposed to be critical environmental factors leading to type 1 diabetes.
A new editorial paper was published in Oncoscience (Volume 10) on September 1, 2023, entitled, “Exiting the pandemic together: achieving global immunity and equity.”
Researchers with the Department of Energy’s SLAC National Accelerator Laboratory and other institutions have been awarded $12 million in funding to help accelerate society’s response to emerging pathogens by improving X-ray science technology and processes.
Older adults who have had cancer had a high risk of experiencing symptoms of depression during the early months of the COVID-19 pandemic according to a new study published in Cancer Management and Research.
El Paso's journey began in March 2020 with its first confirmed case of COVID-19. By fall 2020, the city became the nation’s hotspot.